Russell Pachynski, MD
Medical Oncology · Saint Louis, MONPI 1861568750
Payments from drug & device makers
Across 578 payments — averaging $13,779 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$2.6M
- E.r. Squibb & Sons, L.L.C.$2.2M
- Merck$887K
- Pharmacyclics LLC, An Abbvie Company$658K
- Amgen$536K
- Dendreon Pharmaceuticals LLC$251K
- plus $836K from 28 others
Across 20 payments — averaging $267.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$5K
- EMD Serono, Inc.$752
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 84 | $2,605,356 |
| E.r. Squibb & Sons, L.L.C. | 41 | $2,191,800 |
| Merck | 73 | $886,536 |
| Pharmacyclics LLC, An Abbvie Company | 6 | $658,107 |
| Amgen | 31 | $535,688 |
| Dendreon Pharmaceuticals LLC | 80 | $251,076 |
| Astrazeneca UK Limited | 2 | $174,505 |
| Pfizer | 41 | $152,127 |
| EMD Serono, Inc. | 39 | $133,448 |
| AbbVie | 1 | $127,859 |
| Exelixis Inc. | 10 | $112,433 |
| Bayer | 73 | $53,931 |
| Genentech, Inc. | 14 | $38,230 |
| F. Hoffmann-la Roche AG | 15 | $20,262 |
| Sanofi | 9 | $8,338 |
| Janssen Scientific Affairs, LLC | 7 | $2,841 |
| Medivation LLC. | 1 | $2,652 |
| Eisai Inc. | 3 | $2,565 |
| Tolmar Pharmaceuticals, Inc. | 1 | $1,300 |
| AVEO Pharmaceuticals, Inc. | 8 | $1,277 |
| Blue Earth Diagnostics | 1 | $1,250 |
| AstraZeneca | 11 | $1,208 |
| Gilead | 8 | $380 |
| Novartis | 4 | $308 |
| Inspiremd Ltd | 1 | $143 |
| Seagen Inc. | 1 | $127 |
| Astellas Pharma US Inc | 2 | $126 |
| Clovis Oncology, Inc. | 1 | $119 |
| Johnson & Johnson | 2 | $109 |
| Myovant Sciences Inc. | 1 | $106 |
| Boston Scientific | 1 | $104 |
| Tersera Therapeutics LLC | 3 | $54 |
| Tempus AI, Inc | 2 | $37 |
| Heron Therapeutics, Inc. | 1 | $21 |
How this compares
$7,964,421 in reported general payments places this provider in the 90th percentile of 144 medical oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Saint Louis
- Nina Wagner JohnstonSaint Louis$22M
- Cynthia MaSaint Louis$22M
- Nancy BartlettSaint Louis$19.9M
- Douglas AdkinsSaint Louis$19.2M
- Ramaswamy GovindanSaint Louis$16.4M
- Kelly BoltonSaint Louis$14.5M
- Ravi VijSaint Louis$14.4M
- Daniel MorgenszternSaint Louis$12.8M
- Brad KahlSaint Louis$11.3M
- Camille AbboudSaint Louis$6.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.